Clinical TrialJun 2, 2026, 07:01 AM
iBio Doses First Participant in Phase 1 Trial for IBIO-600
AI Summary
iBio, Inc. announced the dosing of the first participant in its Phase 1 clinical trial for IBIO-600, marking its transition to a clinical-stage biotechnology company. IBIO-600 is a long-acting monoclonal antibody designed to target myostatin and GDF11, aiming to preserve muscle and improve body composition during weight reduction, potentially in combination with GLP-1-based therapies. The study will evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics in approximately 32 adults with overweight and obesity, with results expected in the second half of 2027.
Key Highlights
- iBio dosed the first participant in its Phase 1 clinical trial for IBIO-600.
- IBIO-600 is a long-acting anti-myostatin monoclonal antibody for obesity and cardiometabolic diseases.
- The therapy aims to preserve muscle and improve body composition during weight reduction.
- Non-human primate studies showed IBIO-600 had a 40-52 day half-life and up to 5.1% lean mass gains.
- The Phase 1 trial is a randomized, double-blind, placebo-controlled, single ascending dose study.
- Approximately 32 adults with overweight and obesity are expected to enroll.
- Study completion is anticipated in the second half of 2027.
- iBio's Activin E program IBIO-610 is expected to advance into the clinic in H1 2027.
Price Impact
More from IBIO